126 research outputs found
Biología reproductiva de Neorossia caroli (Cephalopoda: Sepiolidae) en el mar Egeo
A total of 171 specimens of Neorossia caroli were collected by monthly sampling using a bottom trawl with 44-mm mesh size. The depth range of trawls varied between 150 and 550 m. The maximum size (dorsal mantle length, ML) was 41 mm for males and 50 mm for females. Seasonal gonadal stages of both sexes were examined using a gonadosomatic index. It has been observed that the pattern of ovulation of N. caroli is asynchronous and that spawning is continuous. The potential fecundity of females ranged between 317 and 685 oocytes (mean 548). As for males, the number of spermatophores per individual varied between 50 and 71 (mean 61). The smallest female with mature oocytes in the oviduct was 36 mm ML, while the smallest mature male with spermatophores was 20 mm ML. A peak in maturity was observed between July and September. Females appeared to reach larger sizes than males.Se realizó un muestreo mensual con red de arrastre de fondo, cuyo tamaño de mallas en el copo fue de 44 mm, en el mar Egeo en el cual se recolectaron 171 ejemplares de Neorossia caroli. El rango de profundidad de los arrastres varió entre 150 y 550 m. El tamaño máximo (longitud dorsal del manto, LM) fue de 41 mm para los machos y de 50 mm para las hembras. Se examinó la variación estacional de los estadios gonadales de ambos sexos mediante un índice gonadosomático. Se ha observado que el patrón de ovulación de N. caroli es asincrónico y que su freza es continua. La fecundidad potencial de las hembras varió entre 317 y 685 ovocitos (media 548), variando entre 50 y 71 espermatóforos (61 en promedio) en el caso de los machos. La hembra más pequeña con ovocitos maduros en el ovario midió 36 mm de LM, mientras que el macho maduro más pequeño con espermatóforos fue de 20 mm de LM. Se observó la existencia de un pico de puesta entre julio y septiembre. La distri- bución de tallas de ambos sexos mostró que las hembras alcanzan mayores tamaños que los machos
Dinamika populacije mediteranskog zelenog raka Carcinus aestuarii Nardo, 1847. (Crustacea: Portunidae)u delti rijeke Gediz (zaljev Izmir, Istočno Egejsko more)
A total of 6265 Mediterranean green crabs Carcinus aestuarii were sampled from the Gediz Delta in the eastern Aegean Sea (Turkey) during 24 sampling surveys with a 15-day interval from November 2014 to October 2015. The overall ratio of males to females was 1.8:1. Males were predominant in all sampling surveys, except in September 2015. The ranges of total weight (W) and carapace width (CW) for all crabs were 0.19–45.74 g and 8–53 mm. Male crabs were, on average, larger and heavier than females. The W–CW relationships were (W=0.0004×CW^{2.88}) for females, and (W=0.0003×CW^{2.96}) for males. The estimated von Bertalanffy growth parameters for females were: CW∞=49 mm, (K=0.82 year^{-1}) and (t_{0} =-0.9 year), and for males (CW_{∞} = 54 mm), (K=0.92 year^{-1}) and year. The total mortality rates were 2.25 and 2.27 year-1 for females and (t_{0} = -0,96) males, respectively. The breeding season spans from mid fall to early spring peaking in winter. The recruitment of juveniles to the lagoon happens predominantly in summer. The median size at first maturity was 30.6 mm for females and 41.5 mm for males. The average potential fecundity estimate was 63565±36519 oocytes per female crab while the average realized fecundity was 42810±33310 eggs.Sakupljeno je 6265 jedinki mediteranskog zelenog raka Carcinus aestuarii iz delte rijeke Gediz u istočnom Egejskom moru (Turska) tijekom 24 ispitivanja uzoraka u intervalima od 15 dana od studenog 2014. do listopada 2015. godine. Ukupni omjer mužjaka i ženki iznosio je 1:8. Mužjaci su bili prevladavajući u svim istraživanjima uzoraka, osim u rujnu 2015. Rasponi ukupne mase (W) i širine glavopršnjaka (CW) za sve rakove iznosili su 0,19–45,74 g i 8–53 mm. Mužjaci su bili u prosjeku veći i teži od ženki. Odnosi ukupne težine i širine glavopršnjaka su iznosili (W = 0,0004 × CW^{2,88}) za ženke, a (W = 0,0003 × CW^{2,96}) za mužjake. Procijenjeni parametri rasta ženki prema von Bertalanffy-jevoj jednadžbi iznosili su: (CW_{∞}) gdje je = 49 mm, (K = 0,82 godina^{-1}) i (t_{0 = -0,9}) godina, a za mužjake (CW_{∞} = 54 mm), (K = 0,92 godina ^{-1}) i (t_{0} = -0,96) godina. Ukupna smrtnost ženki iznosila je (2,25 godina^-1) dok je za mužjake iznosila (2,27 godina^{-1}). Razdoblje razmnožavanja seže od sredine jeseni do ranog proljeća, te dostiže vrhunac zimi. Novačenje mlađi u laguni se pretežito odvija u ljetnom periodu. Srednja veličina jedinki pri prvoj spolnoj zrelosti bila je 30,6 mm za žene i 41,5 mm za mužjake. Prosječna potencijalna procjena plodnosti iznosila je 63565 ± 36519 oocita po ženki rakova, dok je prosječna ostvarena plodnost iznosila 42810 ± 33310 jajašaca
Reproductive biology of <i>Neorossia caroli</i> (Cephalopoda: Sepiolidae) in the Aegean Sea
Burnout among surgeons before and during the SARS-CoV-2 pandemic: an international survey
Background: SARS-CoV-2 pandemic has had many significant impacts within the surgical realm, and surgeons have been obligated to reconsider almost every aspect of daily clinical practice. Methods: This is a cross-sectional study reported in compliance with the CHERRIES guidelines and conducted through an online platform from June 14th to July 15th, 2020. The primary outcome was the burden of burnout during the pandemic indicated by the validated Shirom-Melamed Burnout Measure. Results: Nine hundred fifty-four surgeons completed the survey. The median length of practice was 10 years; 78.2% included were male with a median age of 37 years old, 39.5% were consultants, 68.9% were general surgeons, and 55.7% were affiliated with an academic institution. Overall, there was a significant increase in the mean burnout score during the pandemic; longer years of practice and older age were significantly associated with less burnout. There were significant reductions in the median number of outpatient visits, operated cases, on-call hours, emergency visits, and research work, so, 48.2% of respondents felt that the training resources were insufficient. The majority (81.3%) of respondents reported that their hospitals were included in the management of COVID-19, 66.5% felt their roles had been minimized; 41% were asked to assist in non-surgical medical practices, and 37.6% of respondents were included in COVID-19 management. Conclusions: There was a significant burnout among trainees. Almost all aspects of clinical and research activities were affected with a significant reduction in the volume of research, outpatient clinic visits, surgical procedures, on-call hours, and emergency cases hindering the training. Trial registration: The study was registered on clicaltrials.gov "NCT04433286" on 16/06/2020
Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019
Five insights from the Global Burden of Disease Study 2019
The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2019 provides a rules-based synthesis of the available evidence on levels and trends in health outcomes, a diverse set of risk factors, and health system responses. GBD 2019 covered 204 countries and territories, as well as first administrative level disaggregations for 22 countries, from 1990 to 2019. Because GBD is highly standardised and comprehensive, spanning both fatal and non-fatal outcomes, and uses a mutually exclusive and collectively exhaustive list of hierarchical disease and injury causes, the study provides a powerful basis for detailed and broad insights on global health trends and emerging challenges. GBD 2019 incorporates data from 281 586 sources and provides more than 3.5 billion estimates of health outcome and health system measures of interest for global, national, and subnational policy dialogue. All GBD estimates are publicly available and adhere to the Guidelines on Accurate and Transparent Health Estimate Reporting. From this vast amount of information, five key insights that are important for health, social, and economic development strategies have been distilled. These insights are subject to the many limitations outlined in each of the component GBD capstone papers.Peer reviewe
Genetic analyses of the electrocardiographic QT interval and its components identify additional loci and pathways.
The QT interval is an electrocardiographic measure representing the sum of ventricular depolarization and repolarization, estimated by QRS duration and JT interval, respectively. QT interval abnormalities are associated with potentially fatal ventricular arrhythmia. Using genome-wide multi-ancestry analyses (>250,000 individuals) we identify 177, 156 and 121 independent loci for QT, JT and QRS, respectively, including a male-specific X-chromosome locus. Using gene-based rare-variant methods, we identify associations with Mendelian disease genes. Enrichments are observed in established pathways for QT and JT, and previously unreported genes indicated in insulin-receptor signalling and cardiac energy metabolism. In contrast for QRS, connective tissue components and processes for cell growth and extracellular matrix interactions are significantly enriched. We demonstrate polygenic risk score associations with atrial fibrillation, conduction disease and sudden cardiac death. Prioritization of druggable genes highlight potential therapeutic targets for arrhythmia. Together, these results substantially advance our understanding of the genetic architecture of ventricular depolarization and repolarization
Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study
Background:
The SARS-CoV-2 delta (B.1.617.2) variant was first detected in England in March, 2021. It has since rapidly become the predominant lineage, owing to high transmissibility. It is suspected that the delta variant is associated with more severe disease than the previously dominant alpha (B.1.1.7) variant. We aimed to characterise the severity of the delta variant compared with the alpha variant by determining the relative risk of hospital attendance outcomes.
Methods:
This cohort study was done among all patients with COVID-19 in England between March 29 and May 23, 2021, who were identified as being infected with either the alpha or delta SARS-CoV-2 variant through whole-genome sequencing. Individual-level data on these patients were linked to routine health-care datasets on vaccination, emergency care attendance, hospital admission, and mortality (data from Public Health England's Second Generation Surveillance System and COVID-19-associated deaths dataset; the National Immunisation Management System; and NHS Digital Secondary Uses Services and Emergency Care Data Set). The risk for hospital admission and emergency care attendance were compared between patients with sequencing-confirmed delta and alpha variants for the whole cohort and by vaccination status subgroups. Stratified Cox regression was used to adjust for age, sex, ethnicity, deprivation, recent international travel, area of residence, calendar week, and vaccination status.
Findings:
Individual-level data on 43 338 COVID-19-positive patients (8682 with the delta variant, 34 656 with the alpha variant; median age 31 years [IQR 17–43]) were included in our analysis. 196 (2·3%) patients with the delta variant versus 764 (2·2%) patients with the alpha variant were admitted to hospital within 14 days after the specimen was taken (adjusted hazard ratio [HR] 2·26 [95% CI 1·32–3·89]). 498 (5·7%) patients with the delta variant versus 1448 (4·2%) patients with the alpha variant were admitted to hospital or attended emergency care within 14 days (adjusted HR 1·45 [1·08–1·95]). Most patients were unvaccinated (32 078 [74·0%] across both groups). The HRs for vaccinated patients with the delta variant versus the alpha variant (adjusted HR for hospital admission 1·94 [95% CI 0·47–8·05] and for hospital admission or emergency care attendance 1·58 [0·69–3·61]) were similar to the HRs for unvaccinated patients (2·32 [1·29–4·16] and 1·43 [1·04–1·97]; p=0·82 for both) but the precision for the vaccinated subgroup was low.
Interpretation:
This large national study found a higher hospital admission or emergency care attendance risk for patients with COVID-19 infected with the delta variant compared with the alpha variant. Results suggest that outbreaks of the delta variant in unvaccinated populations might lead to a greater burden on health-care services than the alpha variant.
Funding:
Medical Research Council; UK Research and Innovation; Department of Health and Social Care; and National Institute for Health Research
Changes in symptomatology, reinfection, and transmissibility associated with the SARS-CoV-2 variant B.1.1.7: an ecological study
Background
The SARS-CoV-2 variant B.1.1.7 was first identified in December, 2020, in England. We aimed to investigate whether increases in the proportion of infections with this variant are associated with differences in symptoms or disease course, reinfection rates, or transmissibility.
Methods
We did an ecological study to examine the association between the regional proportion of infections with the SARS-CoV-2 B.1.1.7 variant and reported symptoms, disease course, rates of reinfection, and transmissibility. Data on types and duration of symptoms were obtained from longitudinal reports from users of the COVID Symptom Study app who reported a positive test for COVID-19 between Sept 28 and Dec 27, 2020 (during which the prevalence of B.1.1.7 increased most notably in parts of the UK). From this dataset, we also estimated the frequency of possible reinfection, defined as the presence of two reported positive tests separated by more than 90 days with a period of reporting no symptoms for more than 7 days before the second positive test. The proportion of SARS-CoV-2 infections with the B.1.1.7 variant across the UK was estimated with use of genomic data from the COVID-19 Genomics UK Consortium and data from Public Health England on spike-gene target failure (a non-specific indicator of the B.1.1.7 variant) in community cases in England. We used linear regression to examine the association between reported symptoms and proportion of B.1.1.7. We assessed the Spearman correlation between the proportion of B.1.1.7 cases and number of reinfections over time, and between the number of positive tests and reinfections. We estimated incidence for B.1.1.7 and previous variants, and compared the effective reproduction number, Rt, for the two incidence estimates.
Findings
From Sept 28 to Dec 27, 2020, positive COVID-19 tests were reported by 36 920 COVID Symptom Study app users whose region was known and who reported as healthy on app sign-up. We found no changes in reported symptoms or disease duration associated with B.1.1.7. For the same period, possible reinfections were identified in 249 (0·7% [95% CI 0·6–0·8]) of 36 509 app users who reported a positive swab test before Oct 1, 2020, but there was no evidence that the frequency of reinfections was higher for the B.1.1.7 variant than for pre-existing variants. Reinfection occurrences were more positively correlated with the overall regional rise in cases (Spearman correlation 0·56–0·69 for South East, London, and East of England) than with the regional increase in the proportion of infections with the B.1.1.7 variant (Spearman correlation 0·38–0·56 in the same regions), suggesting B.1.1.7 does not substantially alter the risk of reinfection. We found a multiplicative increase in the Rt of B.1.1.7 by a factor of 1·35 (95% CI 1·02–1·69) relative to pre-existing variants. However, Rt fell below 1 during regional and national lockdowns, even in regions with high proportions of infections with the B.1.1.7 variant.
Interpretation
The lack of change in symptoms identified in this study indicates that existing testing and surveillance infrastructure do not need to change specifically for the B.1.1.7 variant. In addition, given that there was no apparent increase in the reinfection rate, vaccines are likely to remain effective against the B.1.1.7 variant.
Funding
Zoe Global, Department of Health (UK), Wellcome Trust, Engineering and Physical Sciences Research Council (UK), National Institute for Health Research (UK), Medical Research Council (UK), Alzheimer's Society
- …